Sunshine Biopharma, Inc. (NASDAQ:SBFMW – Get Free Report) saw a large decrease in short interest in August. As of August 14th, there was short interest totaling 773 shares, a decrease of 85.7% from the July 30th total of 5,398 shares. Based on an average daily volume of 190 shares, the short-interest ratio is presently 4.1 days.
Sunshine Biopharma Price Performance
NASDAQ:SBFMW opened at $0.04 on Wednesday. Sunshine Biopharma has a 1-year low of $0.02 and a 1-year high of $0.65. The firm has a fifty day simple moving average of $0.05 and a 200 day simple moving average of $0.09.
About Sunshine Biopharma
Sunshine Biopharma is a development-stage biopharmaceutical company focused on the discovery and development of novel small-molecule therapeutics for oncology and antiviral applications. The company’s research activities encompass the design, synthesis and preclinical evaluation of compounds that inhibit key pathways involved in cell proliferation and viral replication.
Among its lead programs, Sunshine Biopharma is advancing Adva-27a, a topoisomerase II inhibitor licensed from the National Research Council of Canada, which is undergoing preclinical studies for potential use in breast and ovarian cancers.
See Also
- Five stocks we like better than Sunshine Biopharma
- PDD Beat Earnings—So Why Did the Stock Still Fall?
- Tariffs Are Back in Focus: 3 Stocks With a Home-Field Advantage
- Marzetti Stock Confirms Reversal on Earnings Strength, Dividend Growth
- Pathward’s Credit Scare Tests Its Comeback Story
Receive News & Ratings for Sunshine Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunshine Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
